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Solid lipid microparticles (SLMs) loaded with ketoprofen were prepared by 
single emulsion-solvent evaporation method, in which glyceryl monostearate 
and Tween 80 were employed. The particle size was found to be 99.80±2.1μm. 
Microparticles observed by scanning electron microscope (SEM) showed 
spherical shape. The entrapment efficiency (EE %) and drug loading capacity 
(DL %) were found to be 72.60±1.6 % and 17.98±0.7% respectively. Results of 
stability evaluation showed relatively long term stability after storage at 4˚C for 
3 months. The in-vivo study revealed slightly better per cent inhibition of pain 
i.e. 74% in comparison with 68% produced by plain drug.




Las micropartículas lipídicas sólidas (MLS) cargadas con ketoprofeno se 
prepararon a través del método de evaporación del disolvente en emulsión 
simple, en el que se ha utilizado monoestearato de glicerilo y Tween 80. El 
tamaño de la partícula resultó ser de 99,80±2,1 μm. Las micropartículas 
observadas a través del microscopio electrónico de barrido (MEB) mostraron 
una forma esférica. La eficacia de captura (EC %) y la capacidad de carga (CC 
%) del fármaco resultaron ser del 72,60±1,6% y 17,98±0,7%, respectivamente. 
Los resultados de la evaluación de estabilidad mostraron una estabilidad 
relativa a largo plazo, después de una conservación a 4˚C durante 3 meses. 
El estudio in vivo reveló un ligero mejor porcentaje en la inhibición del dolor, 
concretamente, un 74% en comparación con un 68% producido por un fármaco 
corriente. 
PALABRAS CLAVE: Micropartículas lipídicas sólidas, ketoprofeno, método de 
evaporación del disolvente.
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INTRODUCTION
Atorvastatin [R-(R*, R*)]-2-(4-fluorophenyl)-β,∂  dihydroxy-
5-(1-methylethyl)-3-phenyl-4-[(phenyl amino) carbonyl]-
1H-pyrrole-1-heptanoic acid calcium salt for trihydrate] 
is Anti-lipidemic agent act by inhibiting HMG CoA 
reductase enzyme.1 Ramipril [2S-[1[R*(R*)], 2α, 3αβ, 6αβ]]-
1-[2[[1(Ethoxycarbonyl)-3-phenylpropyl] amino]-1-oxon 
propyl] octahydro cyclopenta [b] pyrrole-2-carboxylic 
acid.] is ACE inhibitor.2,3 The combination of both drugs 
is used in treatment of Hypertension. Several HPLC,4-6 
HPTLC,7 Liquid Chromatography–electro Spray Ionization 
Tandem Mass Spectrometry8 methods have been reported 
for atorvastatin alone or in combination with other drugs.9-11 
Only one UV spectroscopy i.e. derivative spectroscopy 
method has been reported for simultaneous estimation of 
Atorvastatin [ATR] and Ramipril [RAM].12 The RP-HPLC 
method for simultaneous estimation of atorvastatin and 
ramipril have been reported from capsule dosage form.13 
The present method (Internal Standard RP-HPLC method) 
quantifies both drugs simultaneously extracted from 
plasma by eliminating interference of endogenous plasma 
components. The method was validated using USFDA 
guidelines for bio-analytical methods.
MATERIALS AND METHODS:
Instrumentation: 
The separation of ATR  and RAM was carried out on an 
isocratic JASCO RP-HPLC system using C18 column 
[150 x 4.6 mm internal diameter, particle size 5µm].The 
pump used in this HPLC system was PU 2080 pump 
[Dual piston with gear driven pump]. The 20 µl sample 
solutions were injected to chromatographic system using 
Rheodyne Injector. The UV detector used in this HPLC 
system was Czerny turners mount monochromater with 
deuterium lamp as light source. The chromatographic 
and the integrated data were recorded using Hercule 2000 
[Interface] computer system. Data processing was carried 
out using Borwin® Version 1.5software.
Reagents and Chemicals: 
The solvents used were of HPLC/AR grade. Pure drug 
samples of ATR, RAM and Valsartan [VAL] are obtained 
as gift samples from Cipla India Pvt. Ltd. Kurkumbh, 
Mumbai. Plasma is prepared by centrifugation of blood 
collected from blood bank.
Chromatographic Conditions:
The analysis was carried out by HPLC using Acetonitrile: 
0.02 M Potassium dihydrogen phosphate (pH 3.2) [80:20 
%V/V] as a mobile phase and HIQ SII C18 column -10 [4.5 
mm x 250 mm] as a stationary phase at a flow rate of 1ml /
minute in an isocratic elution mode. Before delivering the 
mobile phase in to the system, it was degassed and filtered 
through 0.20µm syringe filter. The injection volume was 20 
µl and the detection was performed at 217 nm.14
Preparation of Standard Drug Solutions:
To the 5 ml of blood sample, 10 mg ATR, 20 mg RAM and 
10 % of 0.2 ml trichloroacetic acid were added. Sample 
was centrifuged at 3000 r/m for 35 min. to settle RBCs at 
bottom [15]. The supernatant was separated and volume 
was made up to 10 ml to get the solution 1000 μg/ml of 
each drug. This solution was filtered through syringe filter 
of size 0.45 μm. These solutions were diluted with mobile 
phase to get 100 μg/ml [ATR-10] and 200 μg/ml [RAM-100] 
stock solutions of ATR and RAM respectively.   Standard 
stock solution of VAL was prepared by dissolving 10 mg 
of drug in 80 ml of mobile phase. It was then sonicated 
for 10 min and then final volume was made up to 100 ml 
with mobile phase to get 100 μg/ml of solution in 100 ml 
volumetric flask.
Calibration Curves:
For each drug, appropriate aliquots were pipetted out from 
each standard stock solution into a series of 10 ml volumetric 
flasks. The volume was made up to mark with mobile phase 
to get solutions having concentrations 0.4-25.6 μg/ml , 0.8-
51.2 μg/ml [ increasing geometrically]  and 25 μg/ml in 
each flask for RAM, ATR and VAL respectively. Triplicate 
dilutions of each concentration of each drug were prepared 
separately. From these triplicate solutions, 20 μl injections 
of each concentration of each drug were injected into the 
RP-HPLC system separately and chromatographed under 
the conditions as described above. Evaluation of both 
drugs was performed with UV detector at 217 nm. Peak 
areas were recorded for all the peaks. Retention factors 
were calculated and   plotted against the concentrations to 
obtain the standard calibration curves [Fig. 1]. Using these 
calibration curve data like slope and intercept, it will be 
possible to quantitate concentrations of both drugs. 
Analysis of Quality Control Sample:
For each drug, appropriate aliquots were pipetted out from 
each standard stock solution into three 10 ml volumetric 
flasks. The volume was made up to mark with mobile 
phase to get solutions having concentrations for ATR 0.5, 
2.5 and 25 μg/ml ,for RAM 1, 7 and 50 μg/ml and for 
VAL  25 μg/ml in each flask. Nearly 20 μl injections of 
each concentration of each drug were injected into the RP-
HPLC system separately and chromatographed under the 
conditions as described above [Fig. 2].  Evaluation of both 
drugs was performed with UV detector at 217 nm. Peak 
areas were recorded for all the peaks. Retention factors 
were calculated. The concentrations of both drugs were 
calculated using calibration curve data.
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VALIDATION:
The proposed bio-analytical method was validated as per 
USFDA guidelines.16
Selectivity:
The selectivity of the RP-HPLC method was determined by 
comparison of the chromatogram of blank plasma sample 
[Fig. 3] and quality control samples. The retention times 
peaks present in plasma sample are different than same 
of both drugs thereby proving selectivity of method to 
analyze both drugs with best resolution.
Accuracy and Precision Study: 
The accuracy and precision study was carried out by 
analyzing quality control sample at three concentration 
levels for five times. Precision study was performed to find 
out intra-day and inter-day variations. The results of these 
studies are reported in Table 1.
Extraction Recovery Study:
The recovery of an analyte is the retention factor obtained 
from an amount of the analyte added to and extracted from 
plasma compared to same obtained for the true concentration 
of the quality control sample. Recovery experiments has 
been  performed by comparing the analytical results for 
extracted samples at three concentrations as specified in 
quality control sample analysis with unextracted standards 
that represent 100% recovery. The results of extraction 
recovery are reported in Table 2.  
Limit of Detection [LOD] and Lower Limit of Quantitation 
[LLOQ]:
The LOD and LLOQ were separately determined based 
on the calibration curve data. The standard deviation of 
analyte response and slope of the regression line were 
used. Results of LOD and LLOQ are given in Table 3.
Stability Study:
The stability tests were performed in low and high QC 
samples in terms of short-term storage, long-term storage, 
freeze/thaw stability, post preparative stability and stock 
solution stability. The short-term (room temperature) 
stability was assessed at room temperature for 24 hours 
and long-term stability was assessed at  200C for 45 days. 
Freeze–thaw stability was performed by freeze-thawing for 
4 times specifically. Freezing was performed at  200C for 24 
hours and thawed at room temperature. Post-preparative 
stability was tested by comparing after-day analysis with 
the first intra-day analysis results. It has estimated by 
storing the extracted samples at 100C in an auto-sampler 
for 30 hours. The stock solution stability samples were 
prepared in methanol with water [1:1 ratio] and stored at 
2–80C for 35 days. The samples were further diluted before 
injection. The obtained results were compared with the 
results which were obtained from the freshly prepared 
solutions of the same concentration.
System Suitability Parameters:
System suitability parameters were analyzed on freshly 
prepared standard stock solutions of ATR and RAM. 
Both the drugs were injected into the chromatographic 
system under the optimized chromatographic conditions. 
Parameters that were studied to evaluate the suitability 
of the system were number of theoretical plates, tailing 
factor, resolution, separation factor etc.  These parameters 
are reported in Table 3.17
Day Time
% concentration found* [Mean ± SD] RSD
ATR RAM ATR RAM
I
T1 92.41± 3.7755 91.23 ± 2.9673 4.0322 2.8542
T2 94.14± 3.1389 93.72 ± 4.1569 3.0246 4.2789
T3 90.45± 2.3314 97.41 ± 2.2195 2.5673 2.2785
II
T1 89.20± 1.2104 93.72 ± 4.0325 1.3756 4.1678
T2 92.62± 3.2799 95.03 ± 4.4897 3.3054 4.6213
T3 96.25± 3.8973 90.18 ± 1.5486 3.8249 1.4987
III
T1 97.04± 2.9310 95.13 ± 2.0032 3.0482 2.1852
T2 92.36± 3.1942 94. 87± 4.1025 3.3954 4.2149
T3 97.93± 2.1083 91.20 ± 3.4326 2.2547 3.4219
Analyte Mean Recovery* ± SD RSD
ATR 92.25± 3.8973 3.9345
RAM 91.72 ± 4.0325 4.1925
Table 1: Results of Accuracy and Precision study
Table 2: Result of Extraction Recovery
SD: Standard Deviation; RSD: Relative Standard Deviation. *Average of fifteen determinations.
SD: Standard Deviation; RSD: Relative Standard Deviation. 
*Average of fifteen determinations.
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RESULT AND DISCUSSION:
The proposed method describes a RP-HPLC procedure 
employing a C18 column and a mobile phase containing 
Acetonitrile: 0.02 M Potassium dihydrogen phosphate (pH 
3.2) [80:20 %V/V]. The detection wavelength was 217 nm 
which was selected by analyzing overlain UV spectra of 
ATR and RAM of concentration 10 µg/ml each. Valsartan 
has been selected as an internal standard after observing 
elution behavior and retention times of most of drugs. 
The flow rate of 1ml/min. gives good resolution of both 
drugs.
The ATR and RAM were found be linear in concentration 
range of 0.4 –25.6 µg/ml and 0.8 – 51.2 µg/ml respectively. 
The accuracy and precision study has been carried out by 
analyzing five determinations per concentration [three 
concentrations representing the entire range of the standard 
curve]. The results of accuracy were found be in range of 
89.76 % to 99.89 %. The precision study has been done for 
intra and inters day variations for three consecutive days. 
Extraction recovery was determined by spiking the pure 
drug sample in previously analyzed sample which is more 
than 50 percentages. The stability studies have also proved 
precision of method over long period. The LOD and LLOQ 
values for Atorvastatin were 0.13μg/ml and 0.40 μg/ml, 
for Ramipril 0.29 μg/ml and 0.79 μg/ml respectively thus 
proving sensitivity of method. 
The developed method has found to have least interference 
of endogenous substances form plasma for simultaneous 
estimation of ATR and RAM. The Extraction recovery 
studies revealed excellent efficiency of extraction and 
precision studies showed that method is accurate and 
precise. Low LOD and LLOQ have proven sensitivity 
of method to detect minute quantities of ATR and RAM 
with better accuracy and precision. Thus developed HPLC 
method was found to be more accurate, precise, sensitive, 
selective and reproducible. The developed method has its 
application in pharmacokinetic and bioequivalence study 
of marketed formulations of ATR and RAM.
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